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SUMMARY
Muscle function is regulated by Ca2+, which medi-
ates excitation-contraction coupling, energy meta-
bolism, adaptation to exercise, and sarcolemmal
repair. Several of these actions rely on Ca2+ delivery
to the mitochondrial matrix via the mitochondrial
Ca2+ uniporter, the pore of which is formed by
mitochondrial calcium uniporter (MCU). MCU’s gate-
keeping and cooperative activation are controlled by
MICU1. Loss-of-protein mutation in MICU1 causes a
neuromuscular disease. To determine the mecha-
nisms underlying the muscle impairments, we used
MICU1 patient cells and skeletal muscle-specific
MICU1 knockout mice. Both these models show a
lower threshold for MCU-mediated Ca2+ uptake.
Lack of MICU1 is associated with impaired mito-
chondrial Ca2+ uptake during excitation-contraction,
aerobic metabolism impairment, muscle weakness,
fatigue, and myofiber damage during physical activ-
ity. MICU1 deficit compromises mitochondrial Ca2+
uptake during sarcolemmal injury, which causes inef-
fective repair of the damaged myofibers. Thus, dys-
regulation of mitochondrial Ca2+ uptake hampers
myofiber contractile function, likely through energy
metabolism and membrane repair.
INTRODUCTION
Skeletal muscle (SM) Ca2+ homeostasis is crucial for both
excitation-contraction (EC) coupling and relaxation. When an ac-
tion potential depolarizes the sarcolemmal membrane, L-type
Ca2+ channels are activated and trigger the release of Ca2+
from the ‘‘calcium release units’’ (CRUs) of the sarcoplasmic re-
ticulum (SR) (Franzini-Armstrong, 2018; Hernández-Ochoa et al.,
2016). Ca2+ released from SR through the ryanodine receptor
(RyR) Ca2+ channels binds to troponin, which undergoes a
conformational change and pulls tropomyosin away from the
actin active site allowing cross-bridge formation between actin
and myosin and therefore provoking muscle contraction.
Conversely, to allow relaxation, Ca2+ is pumped back into the
SR, troponin loses its Ca2+, and tropomyosin reverts to its off
position. To match the energy requirements for contraction,
mitochondria adjacent to CRUs take up Ca2+, which in turn stim-
ulates the Krebs cycle and ATP production (Eisner et al., 2013;
Jouaville et al., 1999). SM-derived mitoplasts (representing the
inner mitochondrial membrane [IMM]) display a much greater
Ca2+ current density than other tissues like liver, kidney, and
heart (Fieni et al., 2012), suggesting a pivotal role for mitochon-
drial Ca2+ uptake, specifically in SM function. Nevertheless, the
full extent of the role of mitochondrial Ca2+ uptake in SM function
and disease remains elusive, in part because themolecular iden-
tity of the mitochondrial Ca2+ uniporter (mtCU) complex has
been only recently determined (Baughman et al., 2011; De Ste-
fani et al., 2011; Plovanich et al., 2013; Raffaello et al., 2013; San-
cak et al., 2013).
The first animal model for mitochondrial calcium uniporter
(MCU) deficiency, the pore component of the mtCU complex,
a whole body MCU knockout (MCU/), showed impairment in
exercise capacity and muscle strength (Pan et al., 2013). How-
ever, when the ablation of MCU was achieved in a different ge-
netic mouse background, MCU loss was embryonic lethal
(Murphy et al., 2014). This suggests that mitochondrial Ca2+ up-
take is central to life, and compensatory mechanisms could
explain the discordant phenotypes retrieved in the different
MCU/ models. Very recently, two studies linked striated mus-
cle-specific deletion of MCU to decreased acute exercise and
increased fatty acid utilization, supporting a role of mitochondrial
Ca2+ uptake in contractile function via oxidative metabolism
(Gherardi et al., 2019; Kwong et al., 2018). Genetic manipulation
of MCU expression has also been shown to affect the SM trophic
response in mice (Mammucari et al., 2015), while in human
subjects physical exercise has been demonstrated to cause
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increased protein levels of MCU (Zampieri et al., 2016). To our
knowledge, no pathogenic human MCU mutations have been
described yet, whereas pathogenic mutations in the mtCU
regulatory subunits MICU1 and MICU2 have been described
(Lewis-Smith et al., 2016; Logan et al., 2014; Musa et al., 2019;
Shamseldin et al., 2017), shifting the focus to theMCU regulating
subunits of the mtCU as potential players in pathophysiology.
The Ca2+-sensing protein MICU1 has been characterized as
responsible for gatekeeping and cooperative activation of
MCU (Csordás et al., 2013; Mallilankaraman et al., 2012; Peroc-
chi et al., 2010; Wang et al., 2014), together with its isoform and
potential interacting partner MICU2 (Kamer and Mootha, 2014;
Patron et al., 2014; Plovanich et al., 2013). MICU1 is required
for extrauterine life and for liver regeneration in mice as its loss
leads to sensitization Ca2+ overload-induced mitochondrial
permeability transition pore (PTP) opening in hepatocytes (Ant-
ony et al., 2016). MICU1 is particularly interesting in SM, where
the function is tightly dependent on mitochondrial Ca2+ and the
cells express a specific splicing variant of the protein that confers
to SM mitochondria high responsiveness to sarcoplasmic Ca2+
signals (Vecellio Reane et al., 2016).
With the above studies suggesting a specific and important
role of mtCU in SM function, it is not surprising that abnormal
Ca2+ handling results in SM dysfunction and disease with mito-
chondrial involvement. Mutations in the RyR1, which are associ-
ated with congenital central core myopathy result in enhanced
SR Ca2+ leak, which leads to progressive mitochondrial damage
and decreased ability to generate force (Boncompagni et al.,
2009; Durham et al., 2008; Yang et al., 2003). Abnormal mito-
chondrial Ca2+ handling has also been implicated in the patho-
genesis of Ullrich congenital muscular dystrophy (UCMD) and
Bethlem myopathy (BM), characterized by an increased sensi-
tivity to PTP opening (Angelin et al., 2008; Tiepolo et al., 2009),
leading to activation of a mitochondrial death pathway. Muta-
tions of MICU1 have been linked to a neuronal and muscular dis-
order in humans (Lewis-Smith et al., 2016; Logan et al., 2014).
The patients present with proximal muscle weakness and epi-
sodes of fatigue and lethargy, develop muscle aches after exer-
cise, and during these attacks have elevated levels of creatine
kinase (CK) activity, which is indicative of cell damage due to
the physical stress. Pathological mutations have been described
also for the MICU1 paralog, MICU2. Patients with mutated
MICU2 show encephalopathy with severe cognitive impairment
without a sign of myopathy (Shamseldin et al., 2017). Thus,
lack of MICU1 seems to be of greater consequence for normal
SM physiology.
A commonmechanism of SM degeneration is deficiency in the
mechanism of repair of the sarcolemmal membrane, as already
reported for mouse models for limb girdle muscular dystrophy
2B (Bansal et al., 2003; Cooper and Head, 2015; Defour et al.,
2014b; McGreevy et al., 2015). Membrane repair defects have
been recently linked to lack of MCU, highlighting the importance
of a role for mitochondrial Ca2+ uptake in sarcolemma repair
(Horn et al., 2017). In the mouse model of the lethal muscle dis-
ease Duchenne muscular dystrophy, dysregulation of calcium
and mitochondrial proteins has been shown to be among the
earliest changes and this is associated with poor sarcolemmal
repair (Rayavarapu et al., 2013; Vila et al., 2017).
To address the emerging questions about MICU’s functional
significance and potential disease-causing mechanisms in SM,
we set up a comprehensive approach, including a SM-specific
MICU1 knockout mouse model and MICU1-deficient patient-
derived fibroblasts. We show that lack of MICU1 lowers the acti-
vation threshold for MCU-mediated Ca2+ uptake both in mouse
myofibers and patient fibroblasts, which is reversed by MICU1
re-expression. Lack of MICU1 also alters the cellular Ca2+ ho-
meostasis during myofiber contraction, and leads to increased
signs ofmuscle atrophy, SMweakness, and fatigue. Inmyofibers
with injured sarcolemma, lack of MICU1 inhibits repair by
compromising mitochondrial Ca2+ uptake. MICU1 re-expression
in patient cells enables efficient plasma membrane repair of
these cells. These studies demonstrate the importance of the
regulation of mitochondrial Ca2+ uptake in myofiber function
and repair and offer mechanistic clues to the muscle disease
of the MICU1-deficient patients.
RESULTS
MICU1-Patient Fibroblasts Show a Lower Activation
Threshold for the mtCU Complex
To assess the physiological relevance of MICU1 in human cells,
we obtained dermal fibroblasts from patients with homozygous
MICU1 exon 1 deletion (MICU1-patient) (Lewis-Smith et al.,
2016) and respective controls (CTRLs; CTRL1 and CTRL2). Us-
ing immunoblot analysis, we confirmed the previous report that
the pathogenic patient mutation resulted in loss of MICU1 pro-
tein (Figure 1A). Other components of the mtCU, MICU2, MCU,
and EMRE also showed decreases in patient fibroblasts
compared to CTRL fibroblasts (Figure 1A).
At the transcript level, total MICU1 (MICU1tot) mRNA in patient
fibroblasts was greatly decreased relative to CTRLs (Figure 1B).
However, mRNA levels of the other mtCU members—MICU2,
MCU, and EMRE—were unchanged in the patient. These results
suggest that loss of MICU1might cause instability of some other
proteins of the mtCU complex. Vecellio Reane and colleagues
recently found that SM in mouse has a specific transcript variant
that they namedMICU1.1 (described as variant 2 in theNIH data-
base nucleotide collection, and therefore called MICU1V2 here)
(Vecellio Reane et al., 2016). We could not discriminate between
transcripts of conventional MICU1V1 and MICU1V2 in the human
cells, andmeasured only the amount of total MICU1.While quan-
tifying the transcript levels of these isoforms, we also checked a
third mRNA variant: MICU1V3 (GenBank: NM_144822). This
variant has a distinct 50 UTR, which would cause translation initi-
ation to occur at a start codon downstream to the other variants
of MICU1 (NCBI). The predicted protein encoded by this tran-
script is shorter and has a unique N terminus. Notably, MICU1V3
transcript is also decreased in the patient fibroblasts compared
to CTRLs (Figure 1B).
To assess whether loss of MICU1 perturbs the cytoplasmic
Ca2+ concentration ([Ca2+]c) dependence of the mtCU in the pa-
tient cells, we tested mitochondrial Ca2+ uptake. The plasma
membrane was permeabilized with saponin (40 mg/ml) and ex-
perimentswere performed in the presence of sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) inhibitor thapsigargin (Tg) and
the mitochondrial Na+/Ca2+ exchanger blocker CGP37157 to
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isolate the mtCU-mediated mitochondrial Ca2+ influx. Depen-
dence of mitochondrial uptake rate on [Ca2+]c is shown in the
double-logarithmic plot (Figure 1C). In response to submicromo-
lar [Ca2+]c increases, patient mitochondria displayed Ca
2+ up-
take, whereas CTRL mitochondria showed little response.
Furthermore, MICU1-patient showed significantly less coopera-
tivity in mitochondrial Ca2+ uptake rate as a function of [Ca2+]c
than either of the CTRLs, as shown by the decreased slope of
the double-logarithmic plot (slope = 0.99 ± 0.14 inMICU1-patient
compared to 3.03 ± 0.64 for CTRL1 and 2.94 ± 0.18 for CTRL2,
n = 4). Thus, MICU1-patient fibroblasts reproduced the loss of
gatekeeping and loss of cooperativity in the mitochondrial Ca2+
uptake phenotype previously described in MICU1-deficient
HeLa cells, mouse hepatocytes (Csordás et al., 2013), and
mouse embryonic fibroblasts (MEFs) (Antony et al., 2016).
To further test the relevance of MICU1’s loss in calcium
signaling, we evaluated the [Ca2+]c- and mitochondrial-matrix-
free [Ca2+] ([Ca2+]m) response during store-operated Ca
2+ entry
(SOCE) (Figures 1D and 1E). The ERCa2+ store was pre-depleted
by Tg while the cells were stored in a Ca2+-free buffer. The rise in
[Ca2+]c induced by the addition of 1.5 mM CaCl2 (Ca
2+) (Fig-
ure 1D) was similar in CTRL and MICU1-patient fibroblasts,
generating a [Ca2+]c peak around 250 nM in both cell lines (Fig-
ures 1D and 1F). Measurement of the corresponding [Ca2+]m in
CTRL cells showed no increase, indicating that the threshold
for mtCU activation was not achieved. However, in patient cells
a similar increase in [Ca2+]c was followed by an increase in the
[Ca2+]m (Figures 1E and 1G). The specificity of changes associ-
ated with MICU1 loss in patient fibroblasts was validated by
rescuing dysfunctional [Ca2+]m homeostasis in patient cells by
the expression of an MICU1 HA-tagged construct (MICU1-HA)
(Figure 1H). The presence of MICU1-HA completely abolished
the aberrant [Ca2+]m response detected in MICU1-patient cells
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Figure 1. MCU Complex Composition and
Mitochondrial Ca2+ Handling in Fibroblasts
from MICU1 Loss-of-Function Patients
(A) Representative immunoblots of Hsp70, MICU1,
MICU2, MCU, and EMRE in control (CTRL; CTRL1
and CTRL2) and MICU1-patient fibroblasts. Rela-
tive protein levels are displayed in the bar graph;
each protein was normalized to Hsp70, and ex-
pressed relative to the mean of CTRL1 and CTRL2
fibroblasts (n = 3, *p < 0.05, **p < 0.01).
(B) Relative mRNA levels of total MICU1
(MICU1TOT), transcript variant 3 of MICU1
(MICU1v3), MICU2, MCU, and EMRE. Each tran-
script was normalized to b-actin mRNA, and ex-
pressed relative to the mean of CTRL1 and CTRL2
fibroblasts (n = 3, *p < 0.05).
(C) Double-logarithmic plot of the initial rates of
Ca2+ uptake against the peak free [Ca2+]c. Slope of
each linear fit is indicated. The following total
CaCl2 additions were applied: 3, 4, 5, 6, 10, and
30 mM (mean ± SEM, n = 4). For calculation of the
initial rates linear fits were used because expo-
nentials could not be fit well when the uptake was
small. However, the exponential fit is expected to
be different from the linear fit when the Ca2+
clearance is substantial, so we recalculated
the uptake rates at [Ca2+]c of 15 mM, where the
CTRLs gave 0.116 ± 0.0176 mM/s and the MICU1-
patient showed 0.026 ± 0.0038 mM/s (p < 0.05,
Mann-Whitney), confirming a decrease in the
mitochondrial Ca2+ uptake in the MICU1-patient at
> 10 mM [Ca2+]c.
(D and E) Mean time courses from SOCE-associ-
ated [Ca2+]c (fura2) (D) and [Ca
2+]m (mtCepia) (E)
signals monitored separately in fibroblasts pre-
treated with Tg in a Ca2+-free ECM. To evoke
SOCE, 1.5 mM CaCl2 (Ca
2+) was added (n = 12
cells for each).
(F and G) SOCE-associated [Ca2+]c and [Ca
2+]m
response expressed as difference between peak
and baseline (D[Ca2+]c in [F] and D[Ca
2+]m in [G]).
Experiments were as in (D) and (E), respectively.
(H) Mean traces of the [Ca2+]m responses to SOCE
in MICU1-patient and MICU1-HA-rescued human
fibroblasts (n = 22–24 cells for each).
In all cases, values represent the mean ± SEM.
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what was observed in CTRL fibroblasts. Acute overexpression of
MCU and EMRE accelerated and augmented the [Ca2+]m
response in MICU1-patient cells (Figure S1), indicating that
downregulation of these proteins caused a decrease in the func-
tional mtCUs (Figures 1A and 1B), which likely contributed to a,
presumably adaptive, decrease in the maximal mitochondrial
Ca2+ influx (Figure 1C).
Knockout of MICU1 inMurine SM Impairs mtCU Calcium
Thresholding
To create a stable, striated muscle-specific MICU1 knockout
murine model (MICU1-smKO), C57Bl6 mice expressing Cre re-
combinase under the CK promoter (Ckmm-Cre) were crossed
with mice with floxed MICU1 alleles (MICU1F/F) (Antony et al.,





Figure 2. Ablation of MICU1 in Mouse SM
(A) Representative immunoblots of Hsp70,
MICU1, MICU2, MCU, and EMRE in SM from
CTRL Micu1F/F (CTRL, black bars) and muscle-
specific (CK promoter-drive Cre recombinase)
MICU1 knockout (MICU1-smKO, red bars) mice.
Relative protein levels are displayed in the bar
graph; each protein was normalized to Hsp70, and
expressed relative to CTRL (mean ± SEM, n = 3,
*p < 0.01, **p < 0.001).
(B) Relative mRNA levels of total MICU1
(MICU1TOT), transcript variant 3 of MICU1
(MICU1v3), transcript variant 2 ofMICU1 (MICU1v2;
also known as MICU1.1), transcript variant 1 of
MICU1 (MICU1v1), MICU2, MCU, and EMRE in SM
from CTRL and MICU1-smKO mice. Each tran-
script was normalized to b-actin mRNA and ex-
pressed relative to CTRL (mean ± SEM, n = 3, *p <
0.05, Student’s t test).
(C and D) [Ca2+]m (mtRCaMP) versus [Ca
2+]c
(fura2) curves from individual CTRL (C) and
MICU1-smKO (D) isolated SM fibers. Fibers were
pretreated with Tg in a Ca2+-free ECM. To evoke
SOCE, 2 mM CaCl2 (Ca
2+) was added (n = 15–16
fibers).
(E) Mean traces of the [Ca2+]m responses versus
SOCE-associated [Ca2+]c for CTRL and MICU1-
smKO from (D) and (E), respectively.
(F) [Ca2+]c at which CTRL and MICU1-smKO
fibers showed a 10% increase in [Ca2+]m (ex-
pressed as F/F0 of mtRCaMP). Experiments were
as in (C) and (D).
muscle (Hauser et al., 2000). MICU1F/F
mice were used as the CTRL. Efficient
deletion of MICU1 was confirmed by
immunoblot (Figure 2A) and qPCR anal-
ysis (Figure 2B). As in the human fibro-
blasts, levels of MCU and EMRE proteins
were decreased by 25% and 50%,
respectively (p < 0.01 versus CTRL for
both), without a significant change in the
transcript levels. In contrast to the fibro-
blasts, MICU2 protein was unchanged
withMICU1 depletion. Notably, the abun-
dance of MICU2 is constitutively low in SM relative to other tis-
sues (Paillard et al., 2017). All transcript variants of MICU1,
including the SM-specific variant MICU1V2, were decreased.
We also found a MICU1V3 in the mouse SM and this was
decreased in the MICU1-smKO mice. The mouse MICU1v3
differed from the human MICU1v3 as the mouse-specific
variant lacks two alternate exons in the coding region compared
to MICU1V1. This causes the predicted mouse protein to be
shorter than isoform 1, but with the same N- and C-termini as
in isoform 1.
To test the mitochondrial Ca2+ handling in the myofibers of the
MICU1-smKO mice, flexor digitorum brevis (FDB) muscle in
CTRL and MICU1-smKO mice was electroporated with mito-
chondria-targeted RCaMP (mtRCaMP). After 7–10 days of
expression, individual myofibers were isolated and loaded with
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fura2 to measure [Ca2+]c. The SOCE-induced [Ca
2+]c response
was suppressed in MICU1-smKO (Figure S2A). As in the patient
fibroblasts, the [Ca2+]m response upon SOCE was evaluated in
the myofibers (Figures 2C–2E). Plotting [Ca2+]m against [Ca
2+]c
in eachmyofiber revealed that CTRLmyofibers regularly showed
[Ca2+]m rise once [Ca
2+]c attained 150 nM (Figure 2C), but in
many MICU1-smKO myofibers, [Ca2+]m increase was observed
at [Ca2+]c < 100 nM (Figure 2D). Mean traces confirm a left-
ward-shifted [Ca2+]c dose response for MICU1-smKO relative
to the CTRL (Figure 2E). A 10% increase in [Ca2+]m could be
achieved at [Ca2+]c of 220 ± 2 nM in CTRL and at 120 ± 1 nM
in the MICU1-smKO myofibers (Figure 2F). Altogether, these re-
sults support that MICU1 determines the [Ca2+]c threshold for
mtCU activation in SM, as reported for liver and heart (Antony
et al., 2016; Csordás et al., 2013; Paillard et al., 2017).
MICU1 Ablation Alters the [Ca2+]m Responses to Twitch
and Tetanic Stimulation
Next, we evaluated whether ablation of MICU1 alters SM EC
coupling–associated Ca2+ transients during twitch or repeated
tetanic electrical stimulation (ES). [Ca2+]c transients during twitch
stimulation, measured using the Ca2+ dye fluo4, were similar be-
tween CTRL and MICU1-smKO mice (Figure 3A). Furthermore,
the [Ca2+]m levels measured using rhod2 dye were significantly
decreased in MICU1-smKO myofibers during twitch stimulation
(Figure 3B). Next, we measured absolute [Ca2+]c levels in
response to tetanic stimulation using fura2 that allows calibration
of the absolute [Ca2+]c levels. Baseline [Ca
2+]c (Figure S2B) and
[Ca2+]c transients in response to tetanic stimulation were similar
for MICU1-smKO and CTRL though there was a tendency for
smaller [Ca2+]c transients in the smKO (Figure 3C). To perform ra-
tiometric measurement of the [Ca2+]m response in myofibers,
FDB muscles were co-transfected with the mitochondria-tar-
geted Ca2+ sensor mtRCaMP and also mitochondria-targeted
yellow fluorescence protein (mtYFP). At baseline, the
mtRCaMP/mtYFP ratio was significantly elevated in myofibers
lacking MICU1 (Figure S2C), indicating an elevated basal Ca2+
content. To further confirm high basal [Ca2+]m, we measured
the [Ca2+]c rise caused by Ca
2+ discharge from the mitochondria
induced with FCCP+oligomycin. This increase was larger in
MICU1-smKO than in CTRL (Figure S2D), supporting that
impaired gatekeeping resulted in mitochondrial Ca2+ overload.
During tetanic stimulation, MICU1-smKO myofibers showed a
smaller [Ca2+]m response compared to CTRL mice, consistent
with the observations during twitch stimulation (Figure 3D).
Although the [Ca2+]m peak might be underestimated because
of the normalization to an elevated baseline, the suppression
of the sustained phase of the [Ca2+]m response is evidence for
impaired mitochondrial Ca2+ delivery from SR to mitochondria
in the contracting MICU1-deficient SM.
MICU1 Deficiency Is Associated with Proximal Muscle
Weakness and Muscle Atrophy
Complete loss of mitochondrial Ca2+ uptake has been linked to
impaired SM trophic responses (Mammucari et al., 2015). There-
fore, we tested whether MICU1 ablation affected the size of the
MICU1-smKO muscles. As has been reported in the MICU1-
deficient patients (Logan et al., 2014), we observed that in the
MICU1-smKO mice the mass of both the proximal muscles
examined, quadriceps and triceps, was significantly decreased
(Figure 4A). The mass of the other (distal) muscles and the total
body mass was comparable between CTRL and MICU1-smKO
(Figure S3A). Histological examination of myofiber size in two
different muscles tibialis anterior (TA) and quadriceps from
MICU1-depleted SM showed a trend toward an increased num-
ber of small myofibers (Figure 4B), as was observed when MCU
was deleted in SM (Mammucari et al., 2015). This trend of
smaller-sized myofibers in the MICU1-smKO muscle correlated















































































































Figure 3. MICU1 Is Required for Normal
Ca2+ Transients during SM Contraction
(A and B) Plots showing Ca2+ changes following
twitch stimulation of FDB myofibers from CTRL
and MICU1-smKO mice (100-ms pulse of 20V).
Each fiber received five twitch stimulations (60 s
apart) and these responses were averaged to
obtain a single averaged trace for that fiber (n = 10
CTRL and 14 MICU1-smKO fibers each).
(A) Averaged trace of Fluo-4 intensity after twitch
stimulation. Insert shows peak [Ca2+]c.
(B) Averaged trace showing Rhod-2 intensity after
twitch stimulation. Insert shows peak [Ca2+]m.
Asterisk indicates p < 0.05 by Mann-Whitney test.
(C and D) Repetitive tetanic stimulation of FDB fi-
bers (2-ms pulse at 65 Hz, for 500 ms every 2.5 s)
from CTRL and MICU1-smKO: cytosolic and
mitochondrial Ca2+ results were measured upon
transfection with mtRCaMP, mtYFP (to normalize
for contractile movements), and loading with
Fura-2 AM.
(C) Initial cytosolic Ca2+ transients during 100 tet-
ani ES (n = 14, 12).
(D) Initial mitochondrial Ca2+ transients during 100
tetani ES (n = 9).
In all panels, values are the mean ± SEM.
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with increased expression of the ubiquitin ligase involved in
degradation of contractile proteins, Trim63/Murf-1, and of the
atrophy-related muscle-specific ubiquitin ligase Fbxo32/Atro-
gin-1, indicating activation of myofiber atrophy (Figure 4C). To
evaluate if a canonical Atrogin-1 and MURF-1 pathway is acti-
vated byMICU1 deficiency in the SM, we undertook immunoblot
analysis to quantify the phosphorylated and total levels of AKT,
S6, and AMPK proteins. Our analysis showed no detectable dif-
ferences in this pathway between CTRL and MICU1-smKO
(Figure S3C).
Muscle pathology such as muscular dystrophy is associated
with a change in fiber-type distribution (Marshall et al., 1989; Pe-
demonte et al., 1999). Using antibodies against myosin heavy
chain IIB (MHC-IIB), IIA (MHC-IIB), and 1 (MHC-I), no significant
difference was found in fiber-type composition between CTRL
andMICU1-smKO TAmuscles: type IIB fibers were predominant






































































































































































































































































































) Figure 4. Lack of MICU1 CausesMuscle At-
rophy and Decreased Strength
(A) Plot showing quadriceps and triceps muscle
mass; each dot represents one muscle (*p < 0.05).
(B) Cross sections from TA stained with H&E to
evaluate fiber cross-sectional areas (left; scale
bar, 100 mm). Distribution of the cross-sectional
areas in TA and quadriceps (right; > 100 fibers per
muscle; n = 3 mice/genotype).
(C) Relative mRNA levels of Murf-1 and Atrogin-1.
Each transcript was normalized to b-actin mRNA,
and expressed relative to CTRL (n = 6/genotype,
*p < 0.01, **p < 0.05).
(D and E) Averaged forelimb (D) and hindlimb (E)
grip strength measurement (n = 6 mice each; *p <
0.05).
(F and G) Maximal force developed during (F)
twitch and (G) tetanic stimulation of anterior crural
muscle group (n = 10 muscles/genotype; *p <
0.05).
(H) Treadmill running time during exhaustion pro-
tocol (n = 8).
(I) Blood levels of lactate at rest (n = 14–16) and
after running exhaustion protocol on the treadmill
(n = 8, *p < 0.002).
All bar charts show the mean ± SEM.
almost no (< 1%) MHC-I-positive fibers
were detected, as previously reported
for TA muscle in mice (Kammoun et al.,
2014) (Figures S4A–S4D).
Evidence of possible changes in fiber-
type distribution in human patients was
observed by a reduction in NADH staining
(Logan et al., 2014), indicative of mito-
chondrial dysfunction and loss of type 1
fibers. Consistent with this, we observed
signs of mitochondrial dysfunction in
MICU1-smKO mice by an overall reduc-
tion in NADH labeled fibers (Figure S5A).
However, when we immunoblotted for
an establishedmarker to each respiratory
complex in the quadriceps muscle lysates, no difference was
documented between MICU1-smKO and CTRL (Figure S5B).
Thus, no significant change in the OXPHOS complexes supports
the functional impairment revealed by the NADH labeling.
In view of the above indications of muscle atrophy, we next
tested whether the lack of MICU1 protein affects muscle
strength and endurance. In vivo measurement demonstrated
reduced grip strength in both the forelimbs and hindlimbs of
MICU1-smKO mice (Figures 4D and 4E). In vivo force measure-
ment of the crural muscle group (TA and the extensor digitorum
longus [EDL] muscle) showed that single-twitch stimulation
(pulse width 0.2 ms) elicited a trend for a smaller response in
MICU1-smKO mice (Figure 4F), and maximum force developed
upon tetanic stimulation was clearly lower in MICU1-smKO
mice compared to CTRL (Figure 4G). Next, mice were chal-
lenged in vivo with an exhaustion protocol on a treadmill.
MICU1-smKO mice stayed on the belt less time than CTRL,
Cell Reports 29, 1274–1286, October 29, 2019 1279
but the difference was not significant (Figure 4H). Lack of
elevated serum lactate at rest is a hallmark of MICU1-deficient
patients, which is different from patients suffering from many
other mitochondrial disease-induced myopathies. Therefore,
we measured serum lactate at both rest and also after the tread-
mill running session. Serum lactate levels were comparable be-
tween CTRL andMICU1-smKOmice at rest (Figure 4I). However,
when levels were measured in the same mice immediately after
they ran on a treadmill until exhaustion, we observed higher
serum lactate in MICU1-smKO compared to CTRL mice (Fig-
ure 4I). Altogether, these in vivo changes in the MICU1-smKO
mice indicate both functional and structural impairments,
involving atrophy. Furthermore, the enhanced anaerobic
response to exercise indicates that MICU1 deletion hinders
oxidative metabolism in meeting an increased demand.
MICU1 Is Required for Efficient Plasma Membrane
Repair
Patients with MICU1 mutations have increased serum CK levels,
suggestive of greater myofiber damage (Lewis-Smith et al.,
2016). Consistent with this, we detected elevated resting serum
CK levels in MICU1-smKO mice (Figure 5A). To determine
A B C D
E F G
H I J K
Figure 5. Mouse Myofibers and Patient Fibroblasts Lacking MICU1 Show Poor Plasma Membrane Repair
(A–G) Data from mice.
(A) Serum levels of CK (n = 12 CTRL and 15 MICU1-smKO; *p < 0.02).
(B) Plot showing length of time mice ran voluntarily on a flat treadmill 24 h after eccentric exercise (n = 5 CTRL, 10 MICU1-smKO).
(C and D) Images (scale bar, 50 mm) (C) and quantification (D) of Evan’s blue dye (EBD) uptake in the quadriceps of mice 24 h after eccentric exercise. Wheat germ
albumin (WGA) marks the boundary of individual myofibers (n = 10 CTRL, 8 MICU1-smKO muscles; *p < 0.05).
(E–G) Images (scale bar, 10 mm) (E), kinetics of FM1-43 dye uptake in myofibers after focal laser injury (n = 60 CTRL, 118 MICU1-smKO myofibers) (F), and
quantification of myofibers that failed to repair after laser injury (G). Solid line in (E) marks the boundary of individual myofibers (n = 6 independent experiments;
*p < 0.05).
(H–K) Data from patient fibroblasts.
(H) Plot showing kinetics of FM1-43 dye uptake after focal laser injury in CTRL and MICU1-patient fibroblasts (n = 20 CTRL1, 16 CTRL2, 46 MICU1-patient
fibroblasts).
(I) Quantification of fibroblasts that failed to repair 4 min post focal laser injury (n = 3 independent experiments; *p < 0.05).
(J) Plot showing kinetics of FM1-43 dye uptake after focal laser injury in CTRL-transfected or MICU1-HA-transfected patient fibroblasts (n = 36MICU1-patient, 32
Patient+MICU1-HA fibroblasts).
(K) Quantification of fibroblasts that failed to repair from focal laser injury (n = 4 independent experiments; *p < 0.05).
All values: mean ± SEM.
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whether increased serumCKmay be due to degeneration of my-
ofibers, we first quantifiedmyofiber central nucleation, which is a
measure of regenerating myofibers. We observed no difference
in the amount of centrally nucleated myofibers in CTRL and
MICU1-smKO mice, indicating that myofiber degeneration is
not a driver of muscle pathology in MICU1-deficient mice (Fig-
ure S3B). In contrast to the longer-term process of myofiber
regeneration, myofiber repair occurs on the timescale of minutes
in response to physical damage to the sarcolemma. Previous
work has also shown that mitochondrial Ca2+ uptake deficit is
associated with poor repair of plasma membrane injury in myo-
fibers (Horn et al., 2017). Thus, we next hypothesized that
elevated serum CK in MICU1-smKO mice may be due to an
inability to repair sarcolemmal injury. To directly test if MICU1-
smKO mice show poor myofiber repair, we subjected mice to
eccentric injury by downhill treadmill running (30, running for
30 min). To assess myofiber damage due to physical activity,
Evan’s blue dye (EBD), which is excluded from intact myofibers,
was intra-peritoneally injected in the mice prior to treadmill exer-
cise. Twenty-four hours after eccentric exercise, in vivo muscle
function was tested by running the mice on a level treadmill (no
inclination). CTRL mice ran for 24.7 ± 6.7 min, while the
MICU1-smKOmice ran for 14.1 ± 3.1 min (Figure 5B). To assess
if this reduction in the running capacity of theMICU1-smKOmice
might reflect damaged myofibers, EBD labeling of myofibers
was quantified in the quadriceps muscle. In CTRL mice, 3.6%
± 0.8% of myofibers were labeled with EBD, whereas this num-
ber in MICU1-smKO mice increased by over 5-fold to 18.8% ±
4.1% (Figures 5C and 5D). Altogether, these findings demon-
strate that eccentric muscular activity results in increased myo-
fiber damage in MICU1-smKO myofibers.
To isolate membrane repair capacity from injury magnitude,
we next examined myofiber repair following focal sarcolemmal
injury with a pulsed laser at the same laser power for each myo-
fiber (Defour et al., 2014a). Myofibers in intact bicepsmuscle iso-
lated from CTRL and MICU1-smKO mice were injured by a
pulsed laser in the presence of a membrane impermeant dye
(FM1-43). Dye entry into cells after injury ceases after the sarco-
lemmal injury is repaired, while poor repair leads to prolonged
and hence greater dye entry. Thus, monitoring the extent and
the kinetics of FM-dye entry following a controlled focal injury
provides a direct measure of sarcolemmal repair ability.
Compared to CTRLmyofibers, injury to MICU1-smKOmyofibers
showed prolonged dye entry (Figures 5E and 5F). To assess
whether or not an individual myofiber was able to repair success-
fully, we quantified FM-dye uptake 4 min after injury, a time after
which membrane resealing should have occurred. Only in a cell
that failed to repair should FM-dye still be increasing at this time.
Using this method, we found that only 24.4% ± 4.7% of CTRL
myofibers failed to repair from injury, while 50.7% ± 3.0% of
MICU1-smKO myofibers failed to repair, demonstrating the
poor repair ability of the MICU1-deficient myofibers (Figure 5G).
Mitochondrial dysfunction also compromises repair of other
cells including fibroblasts (Horn et al., 2017). Thus, next we
examined whether MICU1-patient fibroblasts also exhibit poor
plasma membrane repair. Using the FM-dye-based focal laser
injury assay described above for the myofibers, we observed
that injured MICU1-patient fibroblasts also showed greater
FM1-43 dye uptake compared to CTRL healthy human fibro-
blasts (Figure 5H). Further, the inability of MICU1-patient cells
to repair was significantly higher than two CTRL human fibro-
blasts tested (p < 0.05; Figure 5I). To address if poor repair of
the patient fibroblasts was due to the lack of MICU1 protein, pa-
tient fibroblasts were transiently transfected with an MICU1-HA
expressing plasmid. Compared with MICU1-patient fibroblasts,
MICU1-HA transfected patient fibroblasts showed reduced
FM-dye entry, indicating their improved membrane repair ki-
netics (Figure 5J). Further, similar to the CTRL fibroblasts, only
24.3% ± 5.1% of the MICU1-HA-expressing patient fibroblasts
failed to repair compared to 40% of the MICU1-patient fibro-
blasts (Figure 5K). These results demonstrate that loss of
MICU1 protein is sufficient to cause poor plasma membrane
repair in mice and man alike, and occurs both in differentiated
and highly specialized SM fibers as well as in proliferating cells
in culture.
MICU1 Is Required for Mitochondrial Ca2+ Homeostasis
during Sarcolemmal Repair
Poor sarcolemmal repair of MICU1 myofibers may be caused by
mitochondrial Ca2+ uptake deficit in the injured myofibers.
Therefore, we sought to better understand the connection be-
tween regulated mitochondrial Ca2+ uptake and membrane
repair subsequent to sarcolemmal injury. To measure the ki-
netics of the [Ca2+] increase after focal laser injury, individual
FDB myofibers isolated from CTRL and MICU1-smKO mice
were loaded with fluo4 and rhod2 to measure [Ca2+]c and
[Ca2+]m, respectively, in the same myofiber as it repaired from
sarcolemmal damage. Injury caused Ca2+ entry from the extra-
cellular space, resulting in an immediate increase in [Ca2+]c
(Figure 6A). There was no difference in the magnitude of injury-
triggered increase in [Ca2+]c or the time it took for [Ca
2+]c to reach
its peak in CTRL and MICU1-smKO mice (Figures 6B and 6C).
However, clearing the injury-triggered increase in the [Ca2+]c
took nearly three times longer in MICU1-smKO myofibers than
in the CTRL (Figure 6D).
Delayed clearance of the injury-triggered [Ca2+]c increase sug-
gested that loss of MICU1 diminishes the ability of mitochondria
to take up the [Ca2+]c increase caused by sarcolemmal injury.We
previously showed that uptake of [Ca2+]c by mitochondria trig-
gers mitochondrial redox signaling that facilitates sarcolemmal
repair (Horn et al., 2017). Given the role of MICU1 in the cooper-
ative activation of the mtCU, we examined the injury-triggered
uptake of Ca2+ by the mitochondria at peak [Ca2+]c for CTRL
and MICU1-smKO myofibers. At the peak of the injury-triggered
increase in [Ca2+]c, CTRL myofibers showed a 1.6-fold increase
in their [Ca2+]m levels, and this increase was significantly less in
MICU1-smKO (Figure 6E). Furthermore, as compared to the
CTRL, the maximal injury-triggered increase in [Ca2+]m level
was also lower in the MICU1-smKO myofibers (Figure 6F).
Finally, unlike the CTRL myofibers that reached a maximal
[Ca2+]m level in less than 2 s, MICU1-smKO myofibers were
significantly delayed in reaching the maximal [Ca2+]m level
(Figure 6G). Altogether the above results demonstrate that loss
of MICU1 suppresses the injury-triggered increase in [Ca2+]m
within the time window that is critical for the repair of injured
sarcolemma.
Cell Reports 29, 1274–1286, October 29, 2019 1281
DISCUSSION
We have determined the pathophysiological consequences of a
disease-linked MICU1 loss-of-protein mutation in human fibro-
blasts as well as of MICU1 gene deletion in the SM of mice.
The outcomes and the proposed underlying mechanism are de-
picted in Figure 7 and described in detail in the corresponding
figure legend. Briefly, we demonstrated that loss of MICU1 in
SM fibers affects the [Ca2+]m transients during EC coupling
and leads to less contractile force produced upon tetanic stimu-
lation. MICU1-smKO mice show increased fatigue and impaired
adaptation of aerobic metabolism upon exercise. There is
increased muscle atrophy and, similar to the MICU1-patients,
the loss of muscle mass is greater in the proximal muscles.
Both MICU1-deficient SM and patient fibroblasts are also
compromised in their ability to undergo plasma membrane
repair. This deficit results from impaired handling of mitochon-
drial Ca2+ following plasma membrane injury. The mitochondrial
Ca2+ uptake deficit and poor plasma membrane repair are both
rescued by short-term expression of MICU1, establishing the
direct causal relationship between these deficits. Thus, our
mouse model phenocopies the patients’ SM impairments, and
demonstrates the dependence of exercise tolerance and SM
growth and maintenance on how MCU is regulated, not merely
on whether or not there is mitochondrial Ca2+ uptake. Further-
more, this work links the loss of control of mitochondrial Ca2+
to impaired adaptation of oxidative metabolism and exhaustion,
and reveals poor plasma membrane repair as a pathogenic
mechanism for the clinical symptoms, which may be targetable
for therapy.
Patient fibroblasts and the mouse SM display what appears to
be a stereotypical rearrangement of multiple mtCU complex
components upon loss of MICU1 (Figures 1 and 2). Loss of
MICU1 protein is accompanied by a rearrangement of protein
levels of mtCU components, specifically a decrease in EMRE
and MCU, which would result in fewer constitutively active
mtCU pores. It has been shown before that stable deletion of
MICU1 is associated with decreased protein levels of other
mtCU components including EMRE (Liu et al., 2016) and
MICU2 (Kamer and Mootha, 2014; Sancak et al., 2013). But in
some paradigms a different pattern has emerged, notably in
some MICU1-deficient patients, EMRE is increased (Bhosale
et al., 2017). Because we found no changes in the mRNA of
EMRE and MCU that are downregulated at the protein level in
the patient fibroblasts and MICU1KO SM (Figures 1 and 2), we
propose that losing MICU1 results in a destabilized mtCU com-
plex that favors the downregulation of some components. We
hypothesize that an MICU1 deficit induces a negative feedback
loop by increased mtCU Ca2+ flux at resting [Ca2+]c levels, which
suppresses the number of fully functional mtCU complexes and
reduces the risk for Ca2+ overload that can initiate the mitochon-
drial cell death mechanism. The survival benefit of such a mech-
anism has been validated by EMRE deletion in MICU1-KO mice
(Liu et al., 2016). Interestingly, when EMRE is expressed in
excess, it can also inhibit the mtCU complex formation (Tsai
et al., 2017) so the elevation of EMRE might also serve to sup-
press an augmented mtCU-mediated Ca2+ uptake. Neverthe-
less, the spectrum of adaptive mechanisms and their functional
outcome in patients will require future studies involving more
patients.
[Ca2+]m is closely coupled to the [Ca
2+]c rise in the contracting
SM, and the Ca2+ delivery to the mitochondria is dependent on
the MCU (Pan et al., 2013; Rudolf et al., 2004). Our study reveals
that resting [Ca2+]m is higher in MICU1-deficient SM, likely as a
consequence of impaired MCU gatekeeping (Figures 2E and
S2C). Furthermore, the shape of the [Ca2+]m response is deter-
mined by MICU1, and we find that the rise in [Ca2+]m is reduced
both in the twitch contraction and in the tetanic contraction para-
digm. Thismight be caused either by the lack of cooperative acti-
vation of theMCUby [Ca2+]c (Figure 1C), or by the compensatory
downregulation of the pores formed by MCU and EMRE (Fig-
ure 2A). Thus, in SM, MICU1 contributes to the mitochondrial




Figure 6. Lack of MICU1 Alters Cytosolic and Mitochondrial Ca2+
Kinetics following Myofiber Sarcolemma Injury
(A) Plot showing the kinetics of change in cytosolic calcium (measured by
fluo-4) after focal sarcolemmal laser injury.
(B–D) Quantification of data in (A) showing (B) peak [Ca2+]c, (C) time for [Ca
2+]c
to reach the peak, and (D) time for [Ca2+]c to decrease from peak to half-peak
after laser injury.
(E) [Ca2+]m quantified for each myofiber when its [Ca
2+]c was at its peak.
(F) Peak [Ca2+]m after focal laser injury.
(G) Plot showing time to peak [Ca2+]m after focal laser injury. In all cases, n = 13
CTRL and 15 MICU1-smKO myofibers, *p < 0.05.
Values are the mean ± SEM.
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Because the [Ca2+]c responses were not significantly altered in
the MICU1-smKO under the same conditions, the changes in
SM structure and function in this model might be due to the
loss of control in [Ca2+]m rather than that in [Ca
2+]c.
To test the impact of [Ca2+]m in muscle growth and contractile
function,MCUhas been targeted in several recent studies (Gher-
ardi et al., 2019; Kwong et al., 2018; Mammucari et al., 2015).
First, Mammucari et al. observed poor growth in SM upon
silencing of MCU and linked this to impaired signaling through
PGC1a and Akt. Complementing this, they reported enhanced
growth upon overexpression of MCU due to increased
PGC-1a4 and IGF1-Akt/PKB-dependent signaling (Mammucari
et al., 2015). More recently, the same authors reported constitu-
tive and inducible MCU-smKOmodels showing decreasedmus-
cle performance, a fiber-type switch toward fast myosin heavy
chains (MHCs), and ametabolic rewiring toward preferential fatty
acid oxidation (Gherardi et al., 2019). Kwong et al. also created
constitutive and inducible MCU-smKO models in which they re-
ported no change in SM growth or maturation. However, they
also observed a shift to fatty acid preference (Kwong et al.,
2018). Both studies concluded that mitochondrial Ca2+ uptake
determines the fuel selection but in terms of contractile function
they inferred differently. For MICU1, whole body knockouts with
muscle weakness have been reported but in this model it is diffi-
cult to determine the relative contribution of MICU1 deficiency in
SMversus the nervous systemand other tissues (Liu et al., 2016).
In our SM-specific MICU1-deficient mice we show that signs of
muscle weakness and early exhaustion during exercise are
linked to impaired SM growth and increased markers of atrophy
(Figure 4).
In terms of the mechanisms coupling the dysregulation of
[Ca2+]m to impaired maintenance and contractile function, we
have two different leads. First, MICU1 loss has been shown to
impair oxidative metabolism in hepatocytes and patient-derived
cell lines, which has been attributed to ineffective activation of
the Ca2+-sensitive dehydrogenases and other enzymes in the
mitochondrial matrix due to less [Ca2+]m rise during [Ca
2+]c
spikes and oscillations (Csordás et al., 2013; Logan et al.,
2014). Consistent with this, we find that the MICU1-smKO
mice show normal basal lactate levels, as observed in patients
(Musa et al., 2019), but a greater rise upon exercise, which likely
reflects the impaired adaptation of aerobic metabolism (Fig-
ure 4I). It seems plausible that dysregulation of the [Ca2+]m-
dependent steps of oxidative metabolism would be relevant for
muscle fatigue and weakness in the MICU1-smKO mice.
Other components of the MICU1-smKO phenotype and pa-
tient symptoms like the elevated serum CK cannot be explained
by dysregulation of metabolic activity in SM. Our recent studies
have identified a role of mitochondrial Ca2+ uptake in coordi-
nating the repair of injured muscle fibers (Horn et al., 2017).
Further, mitochondrial dysfunction leading to myofiber repair
deficit is linked to the onset of muscle disease (Vila et al.,
2017). We find here that the SM-specific MICU1-deficient mice
poorly tolerate eccentric exercise, which causes myofiber injury,
and they poorly repair their sarcolemmal damage. By targeted
and controlled ex vivo non-mechanical and focal sarcolemmal
injury, we find that it is the inefficient repair (and not other myofi-
brillar deficits) that compromise the ability of the myofibers lack-
ing MICU1 to recover from eccentric exercise-induced damage.
This compromised repair correlates with impaired mitochondrial
uptake of the membrane-injury-triggered increase in [Ca2+]c. As
MICU1 expression can reverse the plasma membrane repair
defect seen in the patient cells, it indicates that the [Ca2+]m up-
take deficit is caused by the lack of MICU1 and not due to an un-
related deficit in the patient cells. This also indicates that the
observed muscle damage and high CK that are a feature of the
MICU1-deficient patients and the MICU1-smKO mouse, arise
from impaired mitochondrial Ca2+ handling that then fails to sup-
port the maintenance of membrane integrity.
An important clinical signature of MICU1-patients is early-
onset proximal muscle weakness, fluctuating fatigue, elevated
serum CK levels upon stress, preserved fiber type but diffuse
variations in fiber size, increased frequency of internal and
central nuclei and clusters of regenerating myofibers without
pronounced fibrosis or fatty infiltration (Lewis-Smith et al.,
2016; Logan et al., 2014). We systematically investigated these
pathological features in MICU1-smKO mice that look outwardly
normal and have normal body weight but show loss of mass in
the proximal muscles: the quadriceps and triceps. The strength
Healthy                                   MICU1KO 
Mitochondrial
Ca2+ uptake:
Rest low                                               high
Stimulation high                                              low
Ca2+ c/m: well coupled                               under coupled
Figure 7. Loss of MICU1 Changes the Functional Coupling between
Cytosolic and Mitochondrial Ca2+ Leading to Lower Fitness of SM
Our study focused on outcomes of SM health in response to resting and
stimulated Ca2+ regimes, in the presence and absence of mtCU regulation by
MICU1. Preventing uniporter regulation led to higher resting [Ca2+]m and less
mitochondrial Ca2+ uptake during stimulation. The changed mitochondrial
Ca2+ phenotypes in response to cytosolic Ca2+ regimes were associated with
lower exercise capacity and muscle mass. We therefore hypothesize that the
functional coupling between cytosolic and mitochondrial Ca2+ (Ca2+ c/m)
contributes to the fitness of SM, and that the regulation of mtCU is an effector
of this coupling.We further propose that contractile performance, metabolism,
and membrane repair are mechanisms that link MICU1 regulation of mtCU to
exercise performance and SM mass. Also represented is the lower EMRE
expression with MICU1 depletion, leading to some nonfunctional mtCUs that
would protect against mitochondrial Ca2+ overload. The lower EMRE
expression with MICU1 loss also suggests that another role for MICU1 is to
contribute to the stability of the mtCU complex.
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of several SM groups was decreased and serum CK levels were
elevated. In the SM histology of a MICU1-patient, some atrophic
myofibers were also noticed (Lewis-Smith et al., 2016). Consis-
tent with this, we also document elevated atrophy markers in
the MICU1-smKO mice. The similarity of the MICU1 SM mouse
phenotype to the patient symptoms suggests that some of the
human symptoms can be attributed directly to MICU1 loss in
SM. However, some symptoms in the patients might be more
severe than in the MICU1-deficient mice because patients also
lack MICU1 in other cell types like the motor neurons; to better
understand the neuronal component of the pathogenesis, a
neuron-specific MICU1 knockout will be needed. Moreover, we
anticipate that the pathology of the MICU1-smKO mice may be
exacerbated by stress, as we previously showed with liver-spe-
cific knockout of MICU1 (Antony et al., 2016; Csordás et al.,
2013). Further, use of the MICU1-smKO model and how it reca-
pitulates patient symptomsmay suggest avenues for developing
and testing therapies for disease caused by MICU1 loss and
possibly also for other mitochondrial myopathies associated
with [Ca2+]m dysregulation.
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Checchetto, V., Moro, S., Szabò, I., and Rizzuto, R. (2013). The mitochondrial
calcium uniporter is a multimer that can include a dominant-negative pore-
forming subunit. EMBO J. 32, 2362–2376.
Rayavarapu, S., Coley, W., Cakir, E., Jahnke, V., Takeda, S., Aoki, Y., Grodish-
Dressman, H., Jaiswal, J.K., Hoffman, E.P., Brown, K.J., et al. (2013).
Identification of disease specific pathways using in vivo SILAC proteomics in
dystrophin deficient mdx mouse. Mol. Cell. Proteomics 12, 1061–1073.
Rudolf, R., Mongillo, M., Magalh~aes, P.J., and Pozzan, T. (2004). In vivo moni-
toring of Ca(2+) uptake into mitochondria of mouse skeletal muscle during
contraction. J. Cell Biol. 166, 527–536.
Sancak, Y., Markhard, A.L., Kitami, T., Kovács-Bogdán, E., Kamer, K.J., Ude-
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exercise in aging human skeletal muscle increases mitochondrial calcium uni-
porter expression levels and affects mitochondria dynamics. Physiol. Rep. 4,
e13005.
1286 Cell Reports 29, 1274–1286, October 29, 2019
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-MICU1 Sigma Aldrich Cat#HPA036480
Rabbit anti-MICU2 Abcam Cat#ab101465
Rabbit anti-MCU Sigma Aldrich Cat#HPA016480; RRID: AB_2071893
Rabbit anti-EMRE Santa Cruz Cat#sc86336 (discontinued)
Mouse anti-Hsp60 Thermo Scientific Cat#MA3-028
Rabbit anti-phospho-AKT (Ser473) Cell Signaling Technology Cat#9271
Rabbit anti-AKT Cell Signaling Technology Cat#9272; RRID: AB_329827
Rabbit anti-phospho-AMPKa (Thr172) Cell Signaling Technology Cat#2535
Rabbit anti-AMPKa Cell Signaling Technology Cat#2532
Rabbit anti-phospho-S6 (ser235/236) Cell Signaling Technology Cat#2211; RRID: AB_331679
Rabbit anti-S6 Ribosomal Protein Cell Signaling Technology Cat#2217; RRID: AB_331355
Mouse Total-OxPhos Cocktail Abcam Cat#ab110411; RRID: AB_2756818
Goat Anti-GRB2 Abcam Cat#ab2234; RRID: AB_2113027
Rabbit anti-laminin Sigma Aldrich Cat#L9393; RRID: AB_477163
Mouse anti-myosin heavy chain Type I Developmental Studies Hybridoma Bank Cat#BA-D5; RRID: AB_2235587
Mouse anti-myosin heavy chain Type2A Developmental Studies Hybridoma Bank Cat#SC-61
Mouse anti-myosin heavy chain Type2B Developmental Studies Hybridoma Bank Cat#BF-F3; RRID: AB_2266724
Chicken anti-rabbit Alexa Fluor488 conjugated to Dylight
488
Invitrogen Cat#A21441; RRID: AB_141735
Goat anti-mouse Alexa Fluor647 conjugated to Dylight 405 Invitrogen Cat#21235; RRID: AB_141693
Chemicals, Peptides, and Recombinant Proteins
DCTM Protein Assay BioRad Cat#5000112
Lipofectamine 3000 Invitrogen Cat#L3000015
Hyaluronidase Type IV Sigma Aldrich Cat#H4272
Collagenase Type 2 Thermo Fisher Cat#16101015
Matrigel BD Biosciences Cat#356234
TRIzol Reagent Ambion Cat#15596018
SuperScript III Invitrogen Cat#18080085
Thapsigargin Enzo Life Sciences Cat#BML-PE180
CGP-37157 Enzo Life Sciences Cat#BML-CM119
Fura2 AM/salt Teflabs Cat# 0-103/0-104
Fura-lowAff AM/salt Teflabs Cat# 0-136/0-0137
Fluo4/AM Invitrogen Cat# F14201
Prolong Gold Mounting Media Life Technologies Cat#P10144
FM1-43 dye Life Technologies Cat#T3163
Critical Commercial Assays
Animal Tissue RNA Purification Kit Norgen Biotek Cat#25700
Enzy Chrome Creatine Kinase Assay Kit BioAssay Systems Cat#ECPK-100
Experimental Models: Cell Lines
Human fibroblasts (Control and MICU1 variant) PMID: 27123478 Patient ‘‘IV:6’’ in PMID: 27123478
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Organisms/Strains
Mouse: MICU1 floxed (MICU1F/F) PMID: 26956930 N/A
Mouse: Ckmm-Cre-MICU1F/F (MICU1-smKO) This paper N/A
Mouse: Tg(Ckmm-Cre) Jackson Laboratories JAX stock# 006475
Oligonucleotides
Genotyping primer (MICU1F/F) FWD GGT GGA GTC AAA
GGG AGG AAC AG
This paper N/A
Genotyping primer (MICU1F/F) REV GCC CCA TCT ATG
ATA ATG TTA AGC
This paper N/A
Genotyping primer (MICU1-smKO) FWD CAG AAC CTG
AAG ATG TTC GC
This paper N/A
Genotyping primer (MICU1-smKO) REV TAC ACC TCG
GTG CTA ACC AG
This paper N/A
qPCR Primers listed in Table S1 This paper N/A
Recombinant DNA
pCMV Cepia3mt PMID: 24923787 Addgene#58219
mtRCaMP PMID: 22784666 N/A
pEYFP-mito Clontech 6115-1
Software and Algorithms
SigmaPlot Systat Software N/A
GraphPad Prism Scientific Software N/A
Slidebook 6.0 Image Acquisition Software Intelligent Imaging Innovations Inc. N/A
CellSens 1.13 Olympus N/A
VS-ASW FL 2.7 Imaging Software Olympus N/A
Other
In situ Muscle Test System 1300A Aurora Scientific N/A
Rodent Treadmill Exer 3/6 Columbus Instruments 1055-SRM
Grip Strength Meter Columbus Instruments 1027SM
Lactate Plus Meter Nova Biomedical N/A
Cryostat CM1900 Leica N/A
Square Pulse Stimulator SD9 Grass Technologies N/A
Oscilloscope NDS-220 Tektronix N/A
Culture/Stimulation Chamber Cell MicroControls N/A
Multiwavelength excitation dual wavelength emission
fluorimeter
Horiba/PTI N/A
Ablate! Pulse Laser 3i Intelligent Imaging Innovations N/A
Zeiss LSM 780 Confocal laser-scanning microscope Carl Zeiss N/A
Zeiss Axio Observer Microscope Carl Zeiss N/A
Leica Inverted DMRE Epi-Fluorescence Microscope Leica N/A
Olympus 1X70 Inverted Fluorescence Microscope Olympus N/A
Olympus BX61 Inverted Fluorescence Microscope Olympus N/A
Olympus 1X81 Inverted Fluorescence Microscope Olympus N/A
CSU-XI Spinning Disc Confocal Unit Yokogawa Electric Co. N/A
Tokai Hit Microscope with ZILCS Incubator Tokai Hit Co. N/A
DFC420 Digital Camera Leica N/A
Evolve 512 EMCCD Camera Photometrics N/A
Olympus XM10 Monochrome Camera Olympus N/A
ProEM 1024 EMCCD Camera Princeton Instruments N/A
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LEAD CONTACT AND MATERIALS AVAILABILITY
Materials Availability Statement: Further information and requests for resources and reagents should be directed to and will be ful-
filled by the Lead Contact, György Hajnόczky, M.D., Ph.D. (Gyorgy.Hajnoczky@Jefferson.edu). There are restrictions to the availabil-
ity of the human fibroblasts from patients having mutations inMICU1 due to the limited availability of these cells and their potential of
these cells to be passaged.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Fibroblasts
Human fibroblasts were obtained from Newcastle University, Newcastle upon Tyne, United Kingdom. MICU1-patient cells were pre-
viously described (patient ‘‘IV:6’’ in Lewis-Smith et al., 2016). The patient is male and was 13 years old at sampling. The 2 controls
were healthy females both age 26 (CTRL1, CTRL2) at sampling. Cells were cultured in Dulbecco’s modified Eagle’s medium (11965-
118, Invitrogen) supplemented with 10% fetal bovine serum, 2 mM glutamine and 100 U/ml penicillin and 100 mg/ml streptomycin in
humidified air (5%CO2) at 37C. Transfection of the cells was performed with plasmid DNA using Lipofectamine 3000 (Invitrogen) for
24-48h following manufacturer’s instructions.
Generation of the MICU1-smKO Mice
Mice were used in accordance with mandated standards of care and were approved by the Thomas Jefferson University Institutional
Animal Care and Use Committee. To obtain MICU1-smKO, the Cre-loxP system was used to target exon 3 of the MICU1 gene for
removal. Homozygous MICU1-floxed (MICU1F/F) mice (on C56BL/6J background) were previously described (Antony et al., 2016).
MICU1F/F micewere then bredwith B6- Tg(Ckmm-Cre) (C56BL/6J background, Jackson Laboratory) mice in which Cre recombinase
is driven by the muscle creatine kinase promoter Tg(Ckmm-Cre). These offspring were bred with homozygous MICU1F/F mice to
establish homozygous MICU1F/F carrying the CKM-cre (MICU1-smKO) transgene. Genotype of mice was determined using the
following primer pairs: 1—50- GGTGGAGTCAAAGGGAGGAACAG-30, and 2—50- GCCCCATCTATGATAATGTTAAGC-30 for floxed
alleles, 3—50-CAGAACCTGAAGATGTTCGC-30 and 4—50TACACCTCGGTGCTAACCAG-30 for Tg(Ckmm-Cre) sequence. Both
male and female mice, 6-8 month of age were used for the experiments.
METHOD DETAILS
In Vivo Electroporation and Harvesting of FDB Fibers for Electrical Stimulation
Transfection of plasmids in FDB muscles of adult mice was performed as described (DiFranco et al., 2009). In brief, mice were anes-
thetized using 5% isoflurane, footpads were injected with 2 mg/ml hyaluronidase type IV (Sigma-Aldrich), and 1 h later, 20 mg total
cDNA was injected (10 ml) followed by electroporation using acupuncture needles as electrodes and delivering 20 pulses of 60 V and
30-ms duration at 1 Hz using a square pulse stimulator (model SD9; Grass Technologies) visualized with an oscilloscope (model TDS
220; Tektronix). Six–10 d after electroporation, mice were euthanized and FDB muscles were harvested. Muscles were digested us-
ing 4 mg/ml collagenase type 2 (16101015, ThermoFisher) for 1 h at 36C under agitation, followed by mechanical dissociation,
adapted from Casas et al. (2010). Isolated fibers were plated onto Matrigel (BD Biosciences)-coated coverslips in DMEM medium
supplemented with Pen/Strep and 10% horse serum (HS), and used within 24 h after plating.
Biochemical Analysis
For western blotting of human fibroblasts, cell lysates were prepared in RIPA buffer supplemented with protease inhibitors (leupetin,
antipain, pepstatin, phenylmethyl sulphonyl fluoride, Sigma). For western blotting from mouse samples, skeletal muscle was har-
vested then homogenized in RIPA buffer or mitochondria were first isolated from skeletal muscles from all limbs as previously
described (Seifert et al., 2008) and then lysed in RIPA buffer as done for the cells. The following antibodies were used for primary
overnight incubation: MICU1 (Sigma (Sg)—HPA036480, 1:400), MICU2 (Abcam (Ab)—ab101465, 1:500), MCU (Sg—HPA016480,
1:500); EMRE (Santa Cruz Biotechnology—sc86336, 1:500), Total-Oxphos (ab110411, 1:500), GRB2 (ab2234, 1:1000), pAMPK
(2535S, 1:1000), AMPK (Cell Signaling Technology (CST)-2532S, 1:1000), pAKT (CST-9271S), AKT (9272S), pS6 (CST-2211S), S6
(CST-2217S) and Hsp60 (Thermo Scientific-MA3-028, 1:1000). Quantification was done using ImageJ (NIH).
RNA Isolation, cDNA Preparation and Quantitative PCR (qPCR)
Total RNA was isolated from frozen mouse quadriceps muscle using Animal Tissue RNA Purification Kit (Norgen Biotek) and from
human fibroblasts using TRIzol reagent (Ambion). RNA concentration was measured by ND-1000 (NanoDrop). cDNA was synthe-
sized using SuperScript III (Invitrogen) and used for qPCR reactions using SYBR Green (Invitrogen) on an ABI Prism 6000 sequence
detection system (Life Technologies). Datawere analyzed using the comparativeDDCtmethod. Ct of the gene of interest was normal-
ized to that of b-actin. Primers used are listed in Table S1.
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Fluorometric Measurements and Live-Cell Imaging
Fluorometric measurements of [Ca2+]c clearance were performed as described (Csordás et al., 2013). Briefly, saponin-permeabilized
fibroblasts (2.4 mg) were resuspended in 1.5 ml of intracellular medium containing 120 mMKCl, 10 mMNaCl, 1 mMKH2PO4, 20 mM
Tris-HEPES at pH 7.2, and supplemented with protease inhibitors (leupetin, antipain, pepstatin, 1 mg ml1 each), 2 mMMgATP, 2 mM
Tg (Enzo) and maintained in a stirred thermostated cuvette at 36 C. Assays were performed in the presence of 20 mM CGP-36156
(Enzo) and 2 mM succinate using a multiwavelength-excitation dual-wavelength-emission fluorimeter (DeltaRAM, PTI). The extrami-
tochondrial Ca2+ concentration [Ca2+]c was assessed using the ratiometric Ca
2+ probe fura2/FA (1.5 mM, Teflabs) or fura-lowAff
(formerly fura/FF; 1 mM, Teflabs). Fura fluorescence was recorded using 340–380 nm excitation and 510 nm emission. Calibration
of the fura signal was carried out at the end of each measurement, adding 1 mM CaCl2, followed by 10 mM EGTA/Tris, pH 8.5.
For imaging experiments, the cells were pre-incubated and loaded with fura2/AM in a serum-free extracellular medium (ECM,
121 mM NaCl, 5 mM NaHCO3, 10 mM Na-HEPES, 4.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2mM CaCl2, 10 mM glucose,
pH7.4) containing 2%BSA. For SOCE experiments ER stores were depleted by 10min pretreatment with 2 mMTg in Ca2+-free buffer.
When both [Ca2+]c and [Ca
2+]m were recorded, excitation filters were as follows: 340/30nm, 380/20nm for fura2, 490/20nm for
mtCepia for human cell lines, or 540/50nm for mtRCaMP and 490/20nm for mtYFP in the case of SM fibers. Data were acquired every
500ms for SOCE and 133ms for fibers ES. Imaging of human fibroblasts was performed using an invertedmicroscope (403, DMRE 2;
Leica), UApo objective (Olympus), and a CCD camera (ProEM 1024 EMCCD camera, Princeton Instruments), while recording of skel-
etal muscle fibers was carried out on anOlympus IX70with UAPO 403 oil 1.3 NA lens. The fura2 ratios were calibrated in terms of nM
[Ca2+]c, whereas the mtCepia and mtRCaMP or mtYFP fluorescence at each time point was normalized to the initial fluorescence
(F/F0).
Myofiber Contraction and Calcium Quantification after Electrical Stimulation and Sarcolemmal Injury
Strips of FDBmuscle from 8month old male mice were placed in 0.2% collagenase in minimal essential media (MEM) with 10% fetal
bovine serum and 1%penicillin/streptomycin (MEM/FBSmedia) and allowed to digest 3-4 h in an incubator (37C, 95%O2-5%CO2).
After 3-4 h, fibers were triturated in MEM/FBS media then left in the incubator until used for experiments. Fibers were assessed for
changes in excitation-contraction coupling within 48h of isolation.
For excitation-contraction coupling measurements during twitch stimulation, fibers were loaded with fluo4/AM (10 mM, Life Tech-
nologies) and rhod2/AM (1 mM) dye in MEM/FBS media for 15 min at room temperature. Media containing dye was then removed by
quick centrifugation, and fibers were resuspended in fresh MEM/FBS media. Fibers were then placed in a culture/stimulation cham-
ber (Cell MicroControls) containing parallel electrodes on top of a microscope stage. In the chamber, fibers were continuously
perfused with a stimulating tyrode solution (121 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2, 0.4 mM NaH2PO4, 24 mM
NaHCO3, and 5.5 mM glucose - pH 7.3). In this preparation, single fibers were unloaded and underwent shortening during electrical
activation. All single fiber data were collected at room temperature (23C). Single muscle fibers were stimulated at 1Hz (Square Pulse
Stimulator, GRASS Technologies) with 1-min rest between stimulations. Images were acquired using an inverted IX81 microscope
(Olympus America) custom equipped with a CSU-X1 spinning disc confocal unit (Yokogawa Electric Corp.). Image acquisition was
controlled using Slidebook 6.0 (Intelligent Imaging Innovations Inc.) and images were acquired for 20ms every 500ms. [Ca2+]c and
[Ca2+]m were measured as the change in fluorescence over the initial fluorescence (F/F0).
For imaging [Ca2+]m simultaneously with [Ca
2+]c in SMduring tetanic stimulation, mtRCaMP/mtYFP transfected fibers were loaded
with fura2/AM. Isolated FDB fibers were electrically stimulated by means of field stimulation as previously described (Eisner et al.,
2014) with the following protocol of stimulation: 100 tetani, 100 Hz, for 500ms every 2.5 s, pulse length 2ms in a custom-made cham-
ber (1 ml, holding two parallel platinum electrodes positioned on each side of the light path, 1 cm apart from each other) connected to
a square pulse stimulator and oscilloscope. The repetitive tetanus frequency was commanded by an external custom-designed mi-
crocontroller. Images (12 triplets/s) were acquired using ex: 340 and 380 nm for fura2 and ex: 545 nm for mtRCaMP, 488 for mtYFP
and a dual band emission filter at a custom built epifluorescence imaging system. For measurement of [Ca2+]c and [Ca
2+]m following
focal sarcolemmal injury, isolated FDBmyofibers were incubated with fluo-4 AM (10 mM, Life Technologies) and rhod-2 (1 mM) dye in
MEM/FBSmedia for 15min at room temperature. After washing with pre-warmed Tyrodemedia, myofibers were quickly centrifuged,
placed on themicroscope stagemaintained at 37C, and injured following the protocol for membrane injury described below. [Ca2+]c
and [Ca2+]m were measured as the change in fluorescence over the initial fluo-4 fluorescence (F/F0).
Measurements of Muscular Contractile Function In Vivo
Male mice were anaesthetized using 4%–5% isoflurane and then 2% isoflurane via a nosecone for maintenance, (both with
1-1.5L/min 100% O2). Rymadil (5mg/kg) was administered before starting the procedure. Briefly, the mouse was kept supine on a
heated limb platform with clamps for affixing the limb. The leg was secured bent in a L shape in the limb plate using a sharpened
screw positioned at the level of the knee. The foot was placed in the footplate, orthogonal to the tibia. Using a transcutaneous elec-
trode, TAmuscle was stimulated and force during plantarflexion was recorded (1300A system, Aurora Scientific Inc.). An in vivo stim-
ulation protocol of a twitch (initial delay 0.2 s, pulsewidth 0.2ms) followed by a tetanus (initial delay 0.2 s, pulse frequency 65Hz, pulse
width 0.2ms, duration 0.8 s) repeated 3 times with a 60 s rest interval was applied.
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Treadmill Running and Eccentric Exercise
The Columbus Instruments Exer 3/6 Treadmill was used to challenge male mice to controlled exercise. An acclimatizing period of
3 days was performed before evaluating the endurance of mice. Running was induced through application of a mild electrical stim-
ulus (16–28 V). To induce running until exhaustion, the treadmill speed was progressively increased from an initial belt speed of
12 m/min to a maximum of 22 m/min. Mice were considered exhausted when they remain on the shock grid for more than R 5 s
without attempting to get back onto the treadmill. Blood lactate levels were measured with a Lactate Plus Meter device (Nova
Biomedical) at rest and immediately after the mouse had stopped running.
To induce in vivo eccentric muscle injury, male mice (6-8 months old) were run on a declined treadmill (Columbus Instruments, Co-
lumbus, OH, USA). The treadmill wasmaintained at a 30 decline and operated at a speed of 8m/min for 30minutes with prodding as
needed to ensure continuous participation. To assess the impact of exercise-induced injury on spontaneous activity, mice were al-
lowed to run freely on a flat treadmill (not inclined) 24 hours after eccentric exercise. Mice were run at a speed of 12 m/min until
fatigued, indicated by the time at which themouse stopped running after 5 successive bouts of prodding at least 30 s apart. For quan-
tification of serum CK, blood was collected by retro orbital sinus puncture 24 hours prior to exercise and again post-exercise. Blood
was centrifuged at 2000 RPM for 15 min at 4C and serum was isolated. CK was measured using the EnzyChrome Creatine Kinase
Assay Kit (ECPK-100, BioAssay Systems, Hayward, CA, USA) as per manufacturer’s instructions. For quantification of muscle injury
and repair, mice were injectedwith Evan’s Blue Dye (EBD) 5 hours prior to eccentric exercise and quadricepsmuscles were collected
after euthanizing, 24 hours post-exercise. Tissueswere sectioned at 8 mmon a Leica CM1900 cryostat.Wheat germ agglutinin (WGA)
conjugated to Alexa Fluor 488 (Life Technologies, MA) was prepared as 1 mg/ml stock solutions and used at 1:500 dilution in PBS.
Sections were mounted with Prolong Gold Mounting Media (Life Technologies, MA) with DAPI for nuclear staining. Microscopy was
performed using an Olympus BX61 VS120-S5 Virtual Slide Scanning System with UPlanSApo 40X/0.95 objective, Olympus XM10
monochrome camera, and Olympus VS-ASW FL 2.7 imaging software. Images were analyzed using Olympus CellSens 1.13 and
ImageJ software.
Grip Strength Measurement
Forelimb and hindlimb grip strength were assessed in 7-8 month old female mice using a grip strength meter as previously described
(Spurney et al., 2009) (Columbus Instruments, Columbus, OH, USA). Mice were acclimated for three consecutive days prior to mea-
surement. An average of five replicates for forelimb and hindlimb was taken for each animal.
Plasma Membrane Repair Assay
Human fibroblasts cultured on coverslips were transferred to Cellular Imaging Medium [CIM; Hanks’ balanced salt solution with
10 mM HEPES, 2 mM CaCl2 (pH 7.4)] and placed in a Tokai Hit microscopy stage-top ZILCS incubator (Tokai Hit Co.) maintained
at 37C. For laser injury, a 1- to 2-mm2 area was irradiated for 10 ms with a pulsed laser (Ablate!, 3i Intelligent Imaging Innovations
Inc.). Cells were imaged using an inverted IX81 microscope (Olympus America) custom equipped with a CSU-X1 spinning disc
confocal unit (Yokogawa Electric Corp.). Images were acquired using Evolve 512 EMCCD (Photometrics) at 1 Hz. Image acquisition
and laser injury was controlled using Slidebook 6.0 (Intelligent Imaging Innovations Inc.). For quantification of plasma membrane,
FM1-43 dye (1 mg/ml, Life Technologies) was added to CIM before injury. FM dye intensity (F/F0, where F0 represents baseline fluo-
rescence) was used to calculate the kinetics of repair. Repair was determined by the entry of FM dye into the cell interior, where a
plateau in FMdye increase indicated successful repair and failure to repair was indicated by unabated FMdye fluorescence increase.
For ex vivo injury of myofibers from intact biceps muscle, mice were euthanized by CO2 asphyxiation and muscles were immediately
dissected. Whole biceps muscles were mounted in prewarmed Tyrode’s buffer [119 mM NaCl, 5 mM KCl, 25 mM HEPES buffer,
2 mM CaCl2, 2 mM MgCl2, glucose (6 g/liter) (pH 7.4)] and imaged using the IX81 Olympus microscope as described above.
Histology
Histology and fiber type staining were performed on TA sections as previously described (Dyar et al., 2013). Hematoxylin/eosin stain-
ing was performed at the translational research /pathology shared resource at Thomas Jefferson University. Bright field images were
acquired using a Zeiss Axio Observer microscope with DFC420 digital camera (Leica). NADH staining was performed using NADH
(Sigma-Aldrich, St. Louis, MO; 8 mg/5 ml) and Nitro-blue tetrazolium (Sigma-Aldrich, St. Louis, MO; 2 mg/ml). Microscopy was
performed using an Olympus BX61 VS120-S5 Virtual Slide Scanning System with UPlanSApo 40X/0.95 objective, Olympus XM10
monochrome camera, and Olympus VS-ASW FL 2.7 imaging software. Images were analyzed using Olympus CellSens 1.13 soft-
ware. Fibers’ Feret’s diameter and cross-sectional area were calculated using ImageJ.
Fiber type staining was performed using anti-laminin antibody (sigma L9393) and the following myosin-heavy chain specific anti-
bodies: BA-D5 (IgG2b, supernatant, 1:100 dilution, specific for MyHC-I; SC-71 (IgG1, supernatant, 1:100 dilution) specific for MyHC-
2A; BF-F3 (IgM, purified antibody, 1:100 dilution) specific for MyHC-2B (Developmental Studies Hybridoma Bank). Secondary
antibodies were as follows: chicken anti-rabbit Alexa Fluor 488 (A21441, Invitrogen to bind laminin), conjugated to DyLight488 fluo-
rophore (to bind either to SC-61 or to BF-F3); goat anti-mouse IgG Alexa Fluor 647 conjugated to DyLight405 fluorophore (to bind to
BA-D5). Image acquisition was performed using 488 nm, 561 nm and 638 laser lines of an LSM780 confocal laser-scanning micro-
scope [20 3 /1.4 NA, PlanApo (Carl Zeiss)]. Image analysis was done using ImageJ software.
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QUANTIFICATION AND STATISTICAL ANALYSIS
Image acquisition and analysis were performed using Slidebook 6.0 or ImageJ software. The statistical analysis was carried out using
the GraphPad Prism Software or SigmaPlot. For all kinetic trace data, individual time points were compared across all cells to deter-
mine significance by unpaired Student’s t test. For all data, the D’Agostino and Pearson omnibus normality test was performed before
determining the appropriate statistical test. For pairwise comparisons, unpaired t tests were used for all normally distributed data,
whereas Mann-Whitney tests were used for nonparametric data. For multiple comparisons, ANOVA followed by Dunnett’s post
hoc test was used to determine significance of normally distributed data. For nonparametric multiple comparisons, a Kruskal-Wallis
test followed by Dunn’s multiple comparison test was used to determine significance (p < 0.05). In all cases, data not indicated as
significant should be considered not statistically different. Replicate information is indicated in the figure legends.
DATA AND CODE AVAILABILITY
Data and Code Availability Statement: The published article includes all [datasets/code] generated or analyzed during this study.
e6 Cell Reports 29, 1274–1286.e1–e6, October 29, 2019
